Glucagon-like peptide-1 (GLP-1) receptor agonists in type 2 diabetes and long-term complications: FOCUS on retinopathy.

Marchand, L; Luyton, C; Bernard, A

Marchand, L; Luyton, C; Bernard, A.

Marchand L; Department of Endocrinology and Diabetes, Centre Hospitalier Saint Joseph Saint Luc, Lyon.
Luyton C; Department of Endocrinology and Diabetes, Centre Hospitalier Saint Joseph Saint Luc, Lyon.
Bernard A; Department of Ophthalmology, Hospices Civils de Lyon, Centre Hospitalier Lyon-Sud, Pierre-Bénite.

Diabet Med ; 38(1): e14390, 2021 01.

Article en En | MEDLINE | ID: mdl-32799379

Asunto(s)

Diabetes Mellitus Tipo 2/complicaciones; Diabetes Mellitus Tipo 2/tratamiento farmacológico; Retinopatía Diabética/epidemiología; Receptor del Péptido 1 Similar al Glucagón/agonistas; Hipoglucemiantes/uso terapéutico; Humanos; Ensayos Clínicos Controlados Aleatorios como Asunto

Palabras clave

ACCORD; ADVANCE; Diabetic Retinopathy; ELIXA; EXSCEL; Eye events; FOCUS; GLP-1; Glucagon-like peptide-1 receptor agonists; HARMONY Outcomes; LEADER; Liraglutide; Lixisenatide; Long-term complications; Microvascular complications; PIONEER-6; REWIND; SUSTAIN-6; Semaglutide; Type 2 Diabetes; UKPDS; VADT; albiglutide; dulaglutide; exenatide; oral semaglutide

Texto completo

Imprimir

XML

PubMed Links

Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Diabetes Mellitus Tipo 2 / Retinopatía Diabética / Receptor del Péptido 1 Similar al Glucagón / Hipoglucemiantes Tipo de estudio: Clinical_trials Límite: Humans Idioma: En Año: 2021 Tipo del documento: Article

Texto completo

Imprimir

XML

PubMed Links

Search on Google